10 unknown, 4 recruiting, 3 not yet recruiting, 2 completed. 11 Phase 2, 7 Phase 3, 3 Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Unknown 6, Recruiting 3, Not yet recruiting 2 |
| Phase 3 | 7 | Unknown 3, Recruiting 2, Completed 1, Terminated 1 |
| Phase 1 | 3 | Unknown 2, Completed 1 |
| Phase 4 | 1 | Not yet recruiting 1 |
Follow potassium oxonate: new trials by email Literature Review of potassium oxonate trials Research Report on potassium oxonate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant and Adjuvant Therapy Studies of Sintilimab Combined With Chemotherapy With or Without Ipilimumab N01 in Resectable Gastric/Gastroesophageal Junction Adenocarcinoma tegafur, Gimeracil and Oteracil Potassium Capsules, Sintilimab Placebo, Sintilimab - Resectable Gastric/Gastroesophageal Junction Adenocarcinoma | Phase 2 / Phase 3 | Recruiting | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | 720 | 2026-07-31 | 2026-08-14 |
| Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer GFH375, Chemotherapy - Metastatic Pancreatic Cancer | Phase 3 | Recruiting | Genfleet Therapeutics (Shanghai) Inc. | 320 | 2025-12-04 | 2026-08-14 |
| A Phase lb/lI Clinical Study in Advanced or Metastatic Esophageal Squamous Cell Carcinoma fruquintinib++Candonilimab+ Tegafur，Gimeracil and Oteracil Potassium - Esophageal Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | Rui-hua Xu, MD, PhD | 70 | 2024-07-10 | 2024-07-05 |
| Effect and Safety of Huaier Granule Versus SOX Regimen in Gastric Cancer Patients Huaier granule, Oxaliplatin, Tegafur, Gimeracil and Oteracil Potassium - Gastric Cancer | Phase 4 | Not yet recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 702 | 2024-07-01 | 2024-06-24 |
| RC48 Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric Cancer RC48, Adebrelimab, Apatinib - Gastric Cancer/Gastroesophageal Junction Adenocarcinoma | Phase 2 | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | 32 | 2024-05-01 | 2024-05-13 |
| Consolidation of Toripalimab After Chemoradiotherapy in Elderly Esophageal Cancer (EC-CRT-007) S-1, Toripalimab, Intensity-modulated radiotherapy - Locally Advanced Esophageal Squamous Cell Carcinoma | Phase 2 | Recruiting | Sun Yat-sen University | 140 | 2024-03-01 | 2024-03-12 |
| A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study LM-302, Toripalimab, Capecitabine - Malignant Neoplasms of Digestive Organs | Phase 2 | Recruiting | LaNova Medicines Zhejiang Co., Ltd. | 632 | 2023-07-27 | 2026-10-19 |
| Fruquintinib Plus S-1 and Raltitrexed (RSF) for MCRC Fruquintinib, S-1, raltitrexed - Fruquintinib, S-1 | Phase 2 | Unknown | Meng Qiu | 66 | 2023-02-20 | 2025-01-22 |
| Conversion Therapy of Disitamab Vedotin Combined With Sintilimab and S-1 in HER2 Overexpression Gastric Cancer Disitamab Vedotin, Sintilimab, S-1 - Gastric Cancer | Phase 2 | Unknown | Tianjin Medical University Cancer Institute and Hospital | 30 | 2023-01-01 | 2022-11-25 |
| A Phase II Study of Gimatecan (ST1481) in Locally Advanced or Metastatic Pancreatic Cancer Gimatecan, tegafur, gimeracil and oteracil potassium, gemcitabine - Pancreatic Cancer | Phase 2 | Unknown | Lee's Pharmaceutical Limited | 60 | 2020-12-01 | 2020-10-01 |
| CCRT Followed by Tegafur, Gimeracil and Oteracil Potassium in Cervical Cancer Tegafur, Gimeracil and Oteracil Potassium Capsules (one drug) - Cervical Cancer, Chemotherapy | Phase 1 / Phase 2 | Unknown | Peking Union Medical College Hospital | 200 | 2020-04-15 | 2020-03-19 |
| SOX Versus XELOX as Adjuvant Chemotherapy for Stage III Colorectal Cancer Patients Oxaliplatin, Tegafur，gimeracil and oteracil potassium, Xeloda - Colorectal Cancer Stage III, Adjuvant Chemotherapy | Phase 3 | Unknown | Peking University Cancer Hospital & Institute | 1191 | 2018-01-01 | 2020-03-06 |
| Adoptive Transfer of Specific HCC Antigens CD8+ T Cells for Treating Patients With Relapsed/Advanced HCC HCC antigens-specific CD8+ T lymphocytes, IL-2, Tegafur - Hepatocellular Carcinoma | Phase 1 | Unknown | Beijing YouAn Hospital | 18 | 2017-05-01 | 2018-01-18 |
| Adoptive Transfer of iNKT Cells for Treating Patients With Relapsed/Advanced HCC iNKT cells, IL-2, Tegafur - Hepatocellular Carcinoma | Phase 1 | Completed | Beijing YouAn Hospital | 10 | 2017-04-01 | 2024-09-19 |
| The Clinical Study of Apatinib Plus S1 for Patients With Advanced Non-squamous Head and Neck Cancer Apatinib, S1 - Head and Neck Neoplasms | Phase 2 | Unknown | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 30 | 2016-10-01 | 2016-10-24 |
| Clinical Study of Endostar Injection Concomitant With SOX Protocols to Treat Advanced Gastric Cancer Oxaliplatin, Gimeracil and Oteracil Potassium Capsule, Endostar injection - Gastric Cancer | Phase 3 | Unknown | Tang Xushan | 120 | 2013-08-01 | 2013-12-11 |
| Neoadjuvant Chemotherapy Plus Chemoradiation in Patients With Potentially Resectable Gastric Carcinoma S1，oxaliplatin，radiation - Gastric Cancer | Phase 2 | Unknown | Fudan University | 40 | 2012-03-01 | 2013-12-31 |
| A Trial Comparing S1 Generic With Capecitabine in Metastatic Breast Cancer (MBC) capecitabine, S1 generic - Metastatic Breast Cancer | Phase 3 | Terminated | Fudan University | 386 | 2012-01-01 | 2018-01-23 |
| Docetaxel+Oxaliplatin+S-1 (DOS) Regimen as Neoadjuvant Chemotherapy in Advanced Gastric Cancer Docetaxel (XRP6976), Oxaliplatin (SR96669), S-1 (1-(2-tetrahydrofuryl)-5-fluorouracil + 5-chloro-2, 4-dihydroxypyridine (CDHP) (Gimeracil) + Oxo (Oteracil) - Gastric Cancer | Phase 3 | Completed | Sanofi | 530 | 2011-12-30 | 2023-12-13 |
| Trial of S-1 Plus Cisplatin in Gastric Cancer s-1 plus cisplatin, 5-Fu plus cisplatin - Gastric Cancer | Phase 3 | Unknown | Sun Yat-sen University | 270 | 2008-09-01 | 2011-07-25 |
Stomach Neoplasms (7) · Carcinoma, Hepatocellular (2) · Esophageal Squamous Cell Carcinoma (2) · Pancreatic Neoplasms (2) · Breast Neoplasms (1) · Colorectal Neoplasms (1) · Head and Neck Neoplasms (1) · Patient Compliance (1) · Uterine Cervical Neoplasms (1)
Beijing YouAn Hospital (2) · Fudan University (2) · Sun Yat-sen University (2) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Genfleet Therapeutics (Shanghai) Inc. (1) · Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. (1) · LaNova Medicines Zhejiang Co., Ltd. (1) · Lee's Pharmaceutical Limited (1) · Meng Qiu (1) · Peking Union Medical College Hospital (1) · Peking University Cancer Hospital & Institute (1) · Rui-hua Xu, MD, PhD (1) · Sanofi (1) · Tang Xushan (1) · The First Affiliated Hospital with Nanjing Medical University (1)
China (16) · South Korea (1)
Aiping Zhou (1) · Aiwen Wu, M.D. (1) · Chunmei Bai (1) · Deliang Fu (1) · Haijiao Yan (1) · Haiping Jiang (1) · Han Liang, Master (1) · Hao Xu, Ph.D (1) · Jieer Ying (1) · Jin Li (1) · Jing Dai (1) · Jun Lu, Director (1) · Jun Zhou (1) · Kaixiong Tao, PhD (1) · Ke Hu, MD (1)
PMID 19139439, PMID 19331206, PMID 21183517, PMID 26439700, PMID 26884585, PMID 29194623, PMID 34133211, PMID 34351356, PMID 35419831, PMID 36990609, PMID 37195667, PMID 38996201, PMID 40022044, PMID 41816563